ADVA
16.12.2020 17:02:35 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that its technology has been selected for Germany’s first open radio access network (O-RAN) proof of concept (PoC). Conducted by Telefónica Germany / O2 , the field trial is a major step towards open and disaggregated RAN architectures. Built on Ensemble Activator , ADVA’s carrier-grade network operating system (NOS) running on Edgecore’s white box switches, and the OSA 5401 , ADVA’s pluggable grandmaster clock and GNSS receiver, the PoC shows how Telefónica Germany / O2 can build disaggregated and vendor-neutral mobile networks that significantly reduce deployment and operational costs. The unique combination of ADVA’s expertise in carrier-grade NOS technology and its Oscilloquartz synchronization solution has enabled this PoC to go beyond other such trials and address the most stringent network timing requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201216005737/en/
“This PoC is an important stage in our journey towards open 5G networking. It shows how we can achieve the scale and agility needed for the widespread rollout of next-generation mobile services and underlines the benefits of vendor collaboration and interoperability,” commented Matthias Sauder, director, mobile access network, Telefónica Germany / O2 . “With this open RAN pilot in our O2 live network, we’re highlighting what can be achieved when industry leaders from across the value chain cooperate closely together in an open environment. We’re also proving that a disaggregated model built on affordable software-empowered hardware can deliver transport infrastructure with new levels of efficiency – for 4G as well as 5G networks in the future.”
The multi-vendor PoC is built on ADVA’s feature-rich Ensemble Activator running on Edgecore’s switching device. Developed as part of the Telecom Infra Project (TIP), the software frees mobile network operators (MNOs) from closed proprietary systems and enables them to create vendor-neutral disaggregated infrastructure with best-of-breed components. The OSA 5401’s time synchronization capabilities are also central to the Telefónica Germany / O2 trial, including its ability to send PTP sync information and corresponding messages with precise timestamping data. The OSA 5401 also makes this advanced operation compatible with 5G radio access points from third-party suppliers and augments the accurate timing needed.
“By harnessing our high-performance NOS and compact timing solution, Telefónica Germany / O2 is taking a big step towards open and disaggregated 5G networking. This PoC shows how it will be able to utilize RAN technology from multiple vendors and leverage the full benefits of separated software and hardware,” said Eli Angel, VP, product line management, ADVA. “As we’re proving in multiple real-world trials with major MNOs, our Ensemble Activator is the ideal choice for turning third-party white box switches from a wide range of suppliers into disaggregated cell site gateways (DCSGs). What’s more, our OSA 5401 provides the strict timing and interoperability needed for an open model. To put it simply, our technology is the key to making open RAN work.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005737/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom